Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
143 participants
OBSERVATIONAL
2011-02-28
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259
Neuro Imaging and Multimodal Alzheimer's Disease
NCT02839187
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
NCT06467981
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
NCT04804722
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
NCT04718207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Memory problems
Group with clinically validated memory problems
No interventions assigned to this group
Reference group
Group without memory problems
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* caucasian
* memory complaint is validated by a clinical evaluation
* cognitive performance is sufficiently well preserved so that a diagnostic of dementia cannot be made (according to the DSM-IV-R and NINCDS-ADRDA criteria) at the time of inclusion
* the patient speaks French
* presence of an informant
* accepts to sign consent
* at least four years of formal education
* patient consulting for memory problems
* memory problem reported by the patient is not validated by the consultation, nor by the battery of tests specified during screening
* presence of an informant
* Clinical Dementia Rating (CDR) = 0
* accepts to sign consent
Exclusion Criteria
* Anticholinesterasic treatments and/or memantin before study inclusion
* major depressive syndrome, according to the Global Depressive Scale
* Known neurodegenerative disease or general disease or major physical problems that could interfere with cognitive functioning and testing
* Pathology that might lead to death in the short term (evolving cancer, non stable cardiopathy, hepatic, renal or respiratory insufficiency)
* contra-indications for MRI, PET or SPECT scans
* not affiliated with a social security regimen
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Olivier Kotzki, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nîmes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Amiens - Hôpital Sud
Amiens, , France
CHU d'Angers - Hôtel-Dieu
Angers, , France
CHU de Besançon - Hôpital Jean Minjoz
Besançon, , France
CHU de Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, , France
APHP - Hôpital Albert Chenevier
Créteil, , France
APHP - Hôpital Charles Foix
Ivry-sur-Seine, , France
CHRU de Lille - Hôpital Claude Huriez
Lille, , France
CHRU de Lille - Hôpital Roger Salengro
Lille, , France
APHP - Hôpital Emile Roux
Limeil-Brévannes, , France
APHM - Hôpital La Timone Adultes
Marseille, , France
CHU de Montpellier - Hôpital Gui de Chauliac
Montpellier, , France
CHU de Nancy - Hôpital Central
Nancy, , France
CHU de Nice - Hôpitaux L'Archet 1 et 2
Nice, , France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, , France
APHP - Hôpital Lariboisière
Paris, , France
APHP - Hôpital Broca
Paris, , France
Groupe Hospitalier Paris Saint-Joseph
Paris, , France
APHP - Groupe Hospitalier Pitié-Salpetrière
Paris, , France
CHU de Poitiers
Poitiers, , France
CHU de Reims - Hôpital Maison Blanche
Reims, , France
CHU de Rouen - Hôpital Charles Nicolle
Rouen, , France
CHRU de Strasbourg - Hôpital de Hautepierre
Strasbourg, , France
CHRU de Toulouse - Hôpital Garonne
Toulouse, , France
CHRU de Toulouse - Hôpital Purpan
Toulouse, , France
CHRU de Tours - Hôpital Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-013476-53
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
PHRC-N/2009/POK-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.